cas 854515-52-9|| where to buy 6-hydroxy-2-methylbenzofuran-3-carboxylic acid

Product Name:6-hydroxy-2-methylbenzofuran-3-carboxylic acid

IUPAC Name:6-hydroxy-2-methyl-1-benzofuran-3-carboxylic acid

Packing Unit	Available Stock	Price($)
CM132795-100mg	in stock	ŌƈŤ
CM132795-250mg	in stock	ŮŤĲ
CM132795-1g	in stock	ƿŮŮ
CM132795-5g	in stock	Ůƿľƿ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 854515-52-9 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:854515-52-9; Molecular Formula:C10H8O4; Melting Point:-; Smiles Code:CC1=C(C(O)=O)C2=C(O1)C=C(O)C=C2; Density:

: Catalog Number:CM132795; Molecular Weight:192.17; Boiling Point:235.838°C at 760 mmHg; MDL No:MFCD12547297; Storage:Store at 2-8°C.

: Benzofurans; Benzofuran is an aromatic heterocyclic organic compound with the chemical formula C8H6O. It is a colorless oily liquid at room temperature with an aromatic odor. Benzofuran can be volatilized with water vapor and can be decomposed by potassium permanganate and other oxidants. It is an intermediate for the preparation of amiodarone and indene resin. Benzofuran derivatives are important pharmaceutical intermediates.; Benzofuran | C8H6O | CID 9223 -Chemenu; Benzofuran | C8H6O | CID 9223 |Where to Buy Benzofurans; Benzofuran is the heterocyclic compound consisting of fused benzene and furan rings. This colourless liquid is a component of coal tar.Benzofuran is extracted from coal tar. It is also obtained by dehydrogenation of 2-ethylphenol.

: Fruquintinib; November 08, 2023, FDA has approved FRUZAQLA(fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
FRUZAQLA is the first and only selective inhibitor of all three VEGF receptor kinases approved in the U.S. for previously treated mCRC regardless of biomarker status.